Iruplinalkib demonstrated promising systemic and intracranial efficacy for NSCLC harbouring <i>SPECC1L-ALK</i> gene, with acceptable and manageable adverse events (for example, grade 3 hypertriglyceridaemia or grade 2 hypercholesterolaemia). This evidence concerns the gene ALK and hypertriglyceridemia.